This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology Rides on Invisalign Amid Coronavirus Woes
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
Buy These 5 Low-Beta Stocks to Survive the Choppy Market
by Nilanjan Banerjee
To combat market volatility, create a portfolio of low-beta stocks.
Here's Why Qiagen (QGEN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Qiagen (QGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes
by Zacks Equity Research
There has been a steady recovery in the Base Business of LabCorp (LH).
Insulet (PODD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.
Thermo Fisher Rides on End Market Growth, Test Revenues
by Zacks Equity Research
Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing
by Zacks Equity Research
The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.
Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic
by Debanjana Dey
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
Blueprint Medicines' Gist Drug Ayvakyt Gets EU Approval
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V mutation.
Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
by Zacks Equity Research
Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
by Zacks Equity Research
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Medtronic Wins Neuromodulation Patent Dispute Against Axonics
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on product launches as well as solid third-quarter of fiscal 2020 results.
Quest Diagnostics Partners in Pilot Program for COVID-19 Test
by Zacks Equity Research
Quest Diagnostics (DGX) to provide online test results for COVID-19 samples collected via drone-delivered at-home self-collection kits as part of a pilot program.
NuVasive Banks on Product Launches Amid Procedural Volume Loss
by Zacks Equity Research
NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.
Boston Scientific, Farapulse Sign Deal for Treatment of AF
by Zacks Equity Research
Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
Abbott's MitraClip G4 Receives CE Mark for Treatment of MR
by Zacks Equity Research
Abbott's (ABT) MitraClip G4 is expected to improve MR patients' quality of life post its usage eligibility in Europe and other countries recognizing the CE Mark.
LabCorp Boosts Oncology Offerings With Resolution ctDx Launch
by Zacks Equity Research
This development comes on the heels of LabCorp's (LH) commercial partnership with non-invasive liquid biopsy platform developer, Resolution Bioscience.
Blueprint Medicines Up on Positive Top-Line Data From SM Study
by Zacks Equity Research
Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares up.
Quest Diagnostics New Tests Uptake Strong Amid Coronavirus Woe
by Zacks Equity Research
Heavy demand for COVID-19 molecular testing helps partially offset the base volume decline for Quest Diagnostics (DGX).
Medtronic TYRX Driveline Gets FDA's Breakthrough Designation
by Zacks Equity Research
This development helps Medtronic (MDT) to augment its research work in the space of interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.